Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Highly variable pharmacokinetics of dexmedetomidine during intensive care: a case report | lirola et al. Journal of Medical Case Reports 2010 4 73 http content 4 1 73 jAg JOURNALOF medical ÌỤr case REPORTS CASE REPORT Open Access Highly variable pharmacokinetics of dexmedetomidine during intensive care a case report Timo Iirola1 Ruut Laitio1 Erkki Kentala1 Riku Aantaa1 Juha-Pekka Kurvinen2 Mika Scheinin2 Klaus T Olkkola1 Abstract Introduction Dexmedetomidine is a selective and potent alpha2-adrenoceptor agonist licensed for use in the sedation of patients initially ventilated in intensive care units at a maximum dose rate of pg kg h administered for up to 24 hours. Higher dose rates and longer infusion periods are sometimes required to achieve sufficient sedation. There are some previous reports on the use of long-term moderate to high-dose infusions of dexmedetomidine in patients in intensive care units but none of these accounts have cited dexmedetomidine plasma concentrations. Case presentation We describe the case of a 42-year-old Caucasian woman with severe hemorrhagic pancreatitis following laparoscopic cholecystectomy who received dexmedetomidine for 24 consecutive days at a maximum dose rate of pg kg h. Samples for the measurement of dexmedetomidine concentrations in her plasma were drawn at intervals of eight hours. On average the observed plasma concentrations were well in accordance with previous knowledge on the pharmacokinetics of dexmedetomidine. There was however marked variability in the concentration of dexmedetomidine in her plasma despite a stable infusion rate. Conclusion The pharmacokinetics of dexmedetomidine appears to be highly variable during intensive care. Introduction Dexmedetomidine is a selective and potent alpha2-adre-noceptor agonist licensed for the sedation of patients initially ventilated in intensive care units ICU at a maximum dose rate of pg kg h administered for up to 24 hours. Higher dose rates and longer infusion periods are sometimes required to achieve sufficient sedation.
